Both the restricted expression of N-Myc in CSCs of HCC and the susceptibility to acyclic retinoid (ACR), one of the derivate chemicals of vitamin A, hold much promise in the novel therapeutic strategy to prevent the recurrence of de novo HCC [159]. This evidence concerns the gene MYCN and hepatocellular carcinoma.